APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Crigler-Najjar Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Crigler-Najjar Syndrome Drug Market Outlook and Growth Opportunities 2026

Report ID 173981490426 December 2025195 pages

Choose your research edition.

Industry ResearchCrigler-Najjar Syndrome Drug Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Crigler-Najjar Syndrome Drug Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Crigler-Najjar Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Crigler-Najjar Syndrome Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Crigler-Najjar Syndrome Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Crigler-Najjar Syndrome Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Crigler-Najjar Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Crigler-Najjar Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Crigler-Najjar Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Crigler-Najjar Syndrome Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Crigler-Najjar Syndrome Drug market include Audentes Therapeutics Inc, Genethon SA, International Stem Cell Corp and Promethera Biosciences SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Crigler-Najjar Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Crigler-Najjar Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Crigler-Najjar Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Crigler-Najjar Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Crigler-Najjar Syndrome Drug Segment by Company

Audentes Therapeutics Inc

Genethon SA

International Stem Cell Corp

Promethera Biosciences SA

Crigler-Najjar Syndrome Drug Segment by Type

ALXN-1540

AT-342

HepaStem

Others

Crigler-Najjar Syndrome Drug Segment by Application

Hospital

Clinic

Others

Crigler-Najjar Syndrome Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Crigler-Najjar Syndrome Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Crigler-Najjar Syndrome Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Crigler-Najjar Syndrome Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Crigler-Najjar Syndrome Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Crigler-Najjar Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Crigler-Najjar Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Crigler-Najjar Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Crigler-Najjar Syndrome Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Crigler-Najjar Syndrome Drug industry.

Chapter 3: Detailed analysis of Crigler-Najjar Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Crigler-Najjar Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Crigler-Najjar Syndrome Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Crigler-Najjar Syndrome Drug Industry Trends Table 2. Crigler-Najjar Syndrome Drug Industry Drivers Table 3. Crigler-Najjar Syndrome Drug Industry Opportunities and Challenges Table 4. Crigler-Najjar Syndrome Drug Industry Restraints Table 5. Global Crigler-Najjar Syndrome Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Crigler-Najjar Syndrome Drug Revenue Share by Company (2021-2026) Table 7. Global Crigler-Najjar Syndrome Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Crigler-Najjar Syndrome Drug Sales Volume Share by Company (2021-2026) Table 9. Global Crigler-Najjar Syndrome Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Crigler-Najjar Syndrome Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Crigler-Najjar Syndrome Drug Key Company Manufacturing Base & Headquarters Table 12. Global Crigler-Najjar Syndrome Drug Company, Product Type & Application Table 13. Global Crigler-Najjar Syndrome Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Crigler-Najjar Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ALXN-1540 Table 18. Significant Companies of AT-342 Table 19. Significant Companies of HepaStem Table 20. Significant Companies of Others Table 21. Global Crigler-Najjar Syndrome Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Crigler-Najjar Syndrome Drug Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Crigler-Najjar Syndrome Drug Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Crigler-Najjar Syndrome Drug Sales Volume Share by Type (2021-2026) Table 25. Global Crigler-Najjar Syndrome Drug Sales Volume Share by Type (2027-2032) Table 26. Global Crigler-Najjar Syndrome Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Crigler-Najjar Syndrome Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Crigler-Najjar Syndrome Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Crigler-Najjar Syndrome Drug Sales Value Share by Type (2021-2026) Table 30. Global Crigler-Najjar Syndrome Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Crigler-Najjar Syndrome Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Crigler-Najjar Syndrome Drug Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Crigler-Najjar Syndrome Drug Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Crigler-Najjar Syndrome Drug Sales Volume Share by Application (2021-2026) Table 38. Global Crigler-Najjar Syndrome Drug Sales Volume Share by Application (2027-2032) Table 39. Global Crigler-Najjar Syndrome Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Crigler-Najjar Syndrome Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Crigler-Najjar Syndrome Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Crigler-Najjar Syndrome Drug Sales Value Share by Application (2021-2026) Table 43. Global Crigler-Najjar Syndrome Drug Sales Value Share by Application (2027-2032) Table 44. Global Crigler-Najjar Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Crigler-Najjar Syndrome Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Crigler-Najjar Syndrome Drug Sales Market Share by Region (2021-2026) Table 47. Global Crigler-Najjar Syndrome Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Crigler-Najjar Syndrome Drug Sales Market Share by Region (2027-2032) Table 49. Global Crigler-Najjar Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Crigler-Najjar Syndrome Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Crigler-Najjar Syndrome Drug Sales Value Share by Region (2021-2026) Table 52. Global Crigler-Najjar Syndrome Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Crigler-Najjar Syndrome Drug Sales Value Share by Region (2027-2032) Table 54. Global Crigler-Najjar Syndrome Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Crigler-Najjar Syndrome Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Crigler-Najjar Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Crigler-Najjar Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Crigler-Najjar Syndrome Drug Sales by Country (2021-2026) & (W Units) Table 59. Global Crigler-Najjar Syndrome Drug Sales Market Share by Country (2021-2026) Table 60. Global Crigler-Najjar Syndrome Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Crigler-Najjar Syndrome Drug Sales Market Share by Country (2027-2032) Table 62. Global Crigler-Najjar Syndrome Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Crigler-Najjar Syndrome Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Crigler-Najjar Syndrome Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Crigler-Najjar Syndrome Drug Sales Value Market Share by Country (2027-2032) Table 66. Audentes Therapeutics Inc Company Information Table 67. Audentes Therapeutics Inc Business Overview Table 68. Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Product Portfolio Table 70. Audentes Therapeutics Inc Recent Development Table 71. Genethon SA Company Information Table 72. Genethon SA Business Overview Table 73. Genethon SA Crigler-Najjar Syndrome Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Genethon SA Crigler-Najjar Syndrome Drug Product Portfolio Table 75. Genethon SA Recent Development Table 76. International Stem Cell Corp Company Information Table 77. International Stem Cell Corp Business Overview Table 78. International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. International Stem Cell Corp Crigler-Najjar Syndrome Drug Product Portfolio Table 80. International Stem Cell Corp Recent Development Table 81. Promethera Biosciences SA Company Information Table 82. Promethera Biosciences SA Business Overview Table 83. Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Promethera Biosciences SA Crigler-Najjar Syndrome Drug Product Portfolio Table 85. Promethera Biosciences SA Recent Development Table 86. Key Raw Materials Table 87. Raw Materials Key Suppliers Table 88. Crigler-Najjar Syndrome Drug Distributors List Table 89. Crigler-Najjar Syndrome Drug Customers List Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Crigler-Najjar Syndrome Drug Product Image Figure 2. Global Crigler-Najjar Syndrome Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Crigler-Najjar Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Crigler-Najjar Syndrome Drug Sales (2021-2032) & (W Units) Figure 5. Global Crigler-Najjar Syndrome Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Crigler-Najjar Syndrome Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ALXN-1540 Image Figure 10. AT-342 Image Figure 11. HepaStem Image Figure 12. Others Image Figure 13. Global Crigler-Najjar Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Crigler-Najjar Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Crigler-Najjar Syndrome Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Crigler-Najjar Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Crigler-Najjar Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Crigler-Najjar Syndrome Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Crigler-Najjar Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Crigler-Najjar Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Crigler-Najjar Syndrome Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Crigler-Najjar Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Crigler-Najjar Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Crigler-Najjar Syndrome Drug Sales Value Share by Application (2021-2032) Figure 28. Global Crigler-Najjar Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Crigler-Najjar Syndrome Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Crigler-Najjar Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Crigler-Najjar Syndrome Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Crigler-Najjar Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Crigler-Najjar Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Crigler-Najjar Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Crigler-Najjar Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Crigler-Najjar Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Crigler-Najjar Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Crigler-Najjar Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Crigler-Najjar Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Crigler-Najjar Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Crigler-Najjar Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Crigler-Najjar Syndrome Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Crigler-Najjar Syndrome Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • ALXN-1540
  • AT-342
  • HepaStem
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Audentes Therapeutics Inc
  • Genethon SA
  • International Stem Cell Corp
  • Promethera Biosciences SA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Crigler-Najjar Syndrome Drug Sales Value (2021-2032)
  4. 1.2.2 Global Crigler-Najjar Syndrome Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Crigler-Najjar Syndrome Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Crigler-Najjar Syndrome Drug Market Dynamics
  1. 2.1 Crigler-Najjar Syndrome Drug Industry Trends
  2. 2.2 Crigler-Najjar Syndrome Drug Industry Drivers
  3. 2.3 Crigler-Najjar Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Crigler-Najjar Syndrome Drug Industry Restraints
3 Crigler-Najjar Syndrome Drug Market by Company
  1. 3.1 Global Crigler-Najjar Syndrome Drug Company Revenue Ranking in 2025
  2. 3.2 Global Crigler-Najjar Syndrome Drug Revenue by Company (2021-2026)
  3. 3.3 Global Crigler-Najjar Syndrome Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Crigler-Najjar Syndrome Drug Average Price by Company (2021-2026)
  5. 3.5 Global Crigler-Najjar Syndrome Drug Company Ranking (2024-2026)
  6. 3.6 Global Crigler-Najjar Syndrome Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Crigler-Najjar Syndrome Drug Company Product Type and Application
  8. 3.8 Global Crigler-Najjar Syndrome Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Crigler-Najjar Syndrome Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Crigler-Najjar Syndrome Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Crigler-Najjar Syndrome Drug Market by Type
  1. 4.1 Crigler-Najjar Syndrome Drug Type Introduction
  2. 4.1.1 ALXN-1540
  3. 4.1.2 AT-342
  4. 4.1.3 HepaStem
  5. 4.1.4 Others
  6. 4.2 Global Crigler-Najjar Syndrome Drug Sales Volume by Type
  7. 4.2.1 Global Crigler-Najjar Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Crigler-Najjar Syndrome Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Crigler-Najjar Syndrome Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Crigler-Najjar Syndrome Drug Sales Value by Type
  11. 4.3.1 Global Crigler-Najjar Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Crigler-Najjar Syndrome Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Crigler-Najjar Syndrome Drug Sales Value Share by Type (2021-2032)
5 Crigler-Najjar Syndrome Drug Market by Application
  1. 5.1 Crigler-Najjar Syndrome Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Crigler-Najjar Syndrome Drug Sales Volume by Application
  6. 5.2.1 Global Crigler-Najjar Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Crigler-Najjar Syndrome Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Crigler-Najjar Syndrome Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Crigler-Najjar Syndrome Drug Sales Value by Application
  10. 5.3.1 Global Crigler-Najjar Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Crigler-Najjar Syndrome Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Crigler-Najjar Syndrome Drug Sales Value Share by Application (2021-2032)
6 Crigler-Najjar Syndrome Drug Regional Sales and Value Analysis
  1. 6.1 Global Crigler-Najjar Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Crigler-Najjar Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Crigler-Najjar Syndrome Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Crigler-Najjar Syndrome Drug Sales by Region (2027-2032)
  5. 6.3 Global Crigler-Najjar Syndrome Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Crigler-Najjar Syndrome Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Crigler-Najjar Syndrome Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Crigler-Najjar Syndrome Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Crigler-Najjar Syndrome Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Crigler-Najjar Syndrome Drug Sales Value (2021-2032)
  12. 6.6.2 North America Crigler-Najjar Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Crigler-Najjar Syndrome Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Crigler-Najjar Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Crigler-Najjar Syndrome Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Crigler-Najjar Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Crigler-Najjar Syndrome Drug Sales Value (2021-2032)
  21. 6.9.2 South America Crigler-Najjar Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Crigler-Najjar Syndrome Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Crigler-Najjar Syndrome Drug Sales Value Share by Country, 2025 VS 2032
7 Crigler-Najjar Syndrome Drug Country-level Sales and Value Analysis
  1. 7.1 Global Crigler-Najjar Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Crigler-Najjar Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Crigler-Najjar Syndrome Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Crigler-Najjar Syndrome Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Crigler-Najjar Syndrome Drug Sales by Country (2027-2032)
  6. 7.4 Global Crigler-Najjar Syndrome Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Crigler-Najjar Syndrome Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Crigler-Najjar Syndrome Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Crigler-Najjar Syndrome Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Crigler-Najjar Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Crigler-Najjar Syndrome Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Audentes Therapeutics Inc
  2. 8.1.1 Audentes Therapeutics Inc Company Information
  3. 8.1.2 Audentes Therapeutics Inc Business Overview
  4. 8.1.3 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Product Portfolio
  6. 8.1.5 Audentes Therapeutics Inc Recent Developments
  7. 8.2 Genethon SA
  8. 8.2.1 Genethon SA Company Information
  9. 8.2.2 Genethon SA Business Overview
  10. 8.2.3 Genethon SA Crigler-Najjar Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Genethon SA Crigler-Najjar Syndrome Drug Product Portfolio
  12. 8.2.5 Genethon SA Recent Developments
  13. 8.3 International Stem Cell Corp
  14. 8.3.1 International Stem Cell Corp Company Information
  15. 8.3.2 International Stem Cell Corp Business Overview
  16. 8.3.3 International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 International Stem Cell Corp Crigler-Najjar Syndrome Drug Product Portfolio
  18. 8.3.5 International Stem Cell Corp Recent Developments
  19. 8.4 Promethera Biosciences SA
  20. 8.4.1 Promethera Biosciences SA Company Information
  21. 8.4.2 Promethera Biosciences SA Business Overview
  22. 8.4.3 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Product Portfolio
  24. 8.4.5 Promethera Biosciences SA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Crigler-Najjar Syndrome Drug Value Chain Analysis
  2. 9.1.1 Crigler-Najjar Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Crigler-Najjar Syndrome Drug Sales Mode & Process
  6. 9.2 Crigler-Najjar Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Crigler-Najjar Syndrome Drug Distributors
  9. 9.2.3 Crigler-Najjar Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst